Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of ~~Compounds of the general~~ formula (I)



(I)

in which

R^1 represents phenyl or represents 5- or 6-membered heteroaryl having up to two heteroatoms from the group consisting of N, O and S, which radicals may for their part each be mono- to trisubstituted by identical or different substituents selected from the group consisting of halogen, cyano, nitro, (C_1-C_6)-alkyl (which for its part may be substituted by hydroxyl), (C_1-C_6)-alkoxy, trifluoromethyl, trifluoromethoxy, (C_1-C_6)-alkylsulphonyl, (C_1-C_6)-alkanoyl, (C_1-C_6)-alkoxycarbonyl, carboxyl, amino, (C_1-C_6)-acylamino, mono- and di-(C_1-C_6)-alkylamino,

R^2 and R^3 are identical or different and independently of one another represent hydrogen or (C_1-C_4)-alkyl or together with the carbon atom to which they are attached form a 3- to 7-membered spiro-linked cycloalkyl ring,

R^4 represents hydrogen or (C_1-C_4)-alkyl,

R^5 represents hydrogen, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy or halogen,

R^6 represents (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, (C_1-C_6)-alkanoyl, (C_1-C_6)-alkylsulphonyl or (C_1-C_6)-alkoxycarbonyl,

R^7 and R^8 are identical or different and independently of one another represent hydrogen or (C_1-C_4)-alkyl,

and

R^9 represents hydrogen or a hydrolyzable group which can be degraded to the corresponding carboxylic acid,

or a ~~and their~~ pharmaceutically acceptable salt thereof ~~salts, solvates and solvates of the salts~~ .

2. (currently amended) The compound of ~~Compounds of the general formula (I) according to~~ Claim 1 in which

R^1 represents phenyl which may be mono- or disubstituted by identical or different substituents selected from the group consisting of fluorine, chlorine, cyano, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy, trifluoromethyl, trifluoromethoxy, methylsulphonyl, acetyl, propionyl, (C_1-C_4)-alkoxycarbonyl, amino, acetylamino, mono- and di-(C_1-C_4)-alkylamino,

R^2 and R^3 are identical or different and independently of one another represent hydrogen or (C_1-C_4)-alkyl or together with the carbon atom to which they are attached form a 5- or 6-membered spiro-linked cycloalkyl ring,

R^4 represents hydrogen or methyl,

R^5 represents hydrogen, methyl, methoxy, fluorine or chlorine,

R^6 represents (C_1-C_4)-alkyl, acetyl, methylsulphonyl, methoxycarbonyl or tert-butoxycarbonyl,

R^7 and R^8 are identical or different and independently of one another represent hydrogen or methyl,

and

R^9 represents hydrogen.

3. (currently amended) The compound of ~~Compounds of the general formula (I) according to~~ Claim 1 in which

R^1 represents phenyl which may be mono- or disubstituted by identical or different substituents selected from the group consisting of fluorine, chlorine, methyl, trifluoromethyl and trifluoromethoxy,

R^2 represents methyl,

R^3 represents methyl,

or

R^2 and R^3 together with the carbon atom to which they are attached form a spiro-linked cyclopentane or cyclohexane ring,

R^4 represents hydrogen or methyl,

R^5 represents hydrogen, methyl, fluorine or chlorine,

R^6 represents (C_1-C_4)-alkyl, acetyl or methylsulphonyl,

R^7 and R^8 each represent hydrogen

and

R^9 represents hydrogen.

4. (currently amended) A compound of ~~Compounds of the~~ formula (I-A)



(I-A)

in which

R^1 represents phenyl which is substituted by fluorine, chlorine or trifluoromethyl,

and

R^6 represents methyl, ethyl, n-propyl, isopropyl or tert-butyl.

5. (currently amended) A process ~~Process~~ for preparing a compound of claim 1 or 4, comprising initially converting a compound ~~the compounds of the general formula (I) or (I-A) as defined in Claims 1 to 4, characterized in that compounds~~ of the formula (II)



(II)

in which

R^2, R^3 and R^4 are each as defined in Claim 1

and

Y represents chlorine or bromine

~~are initially~~ , by methods known from the literature, ~~converted~~ into a compound ~~compounds~~ of the formula (III)



(III)

in which

Y, R^2, R^3 and R^4 are each as defined in Claim 1

and

PG represents a suitable amino protective group ~~, preferably 4-nitrophenylsulphonyl,~~ then reacting this compound ~~these compounds are then reacted~~ in a coupling reaction with a compound of the formula (IV)



(IV)

in which

R^1 is as defined in Claim 1

and

R^{10} represents hydrogen or methyl or both radicals together form a CH_2CH_2- or $C(CH_3)_2$-$C(CH_3)_2$-bridge

in an inert solvent in the presence of a suitable palladium catalyst and a base to give a compound ~~compounds~~ of the formula (V)



(V)

in which

PG, R^1, R^2, R^3 and R^4 are each as defined in Claim 1,

then again removing the protective group PG ~~is then~~ , by methods known from the literature, ~~removed again~~ giving a compound ~~compounds~~ of the formula (VI)



(VI)

in which

R^1, R^2, R^3 and R^4 are each as defined in Claim 1,

then converting the product ~~is then converted~~ with a compound of the formula (VII)



(VII)

in which

R^5, R^6, R^7 and R^8 are each as defined in Claim 1

and

T represents benzyl or $(C_1$-$C_6)$-alkyl

in an inert solvent in the presence of a base into a compound ~~compounds~~ of the formula (VIII)



(VIII)

in which

T, R^1, R^2, R^3, R^4, R^5, R^6, R^7 and R^8 are each as defined in Claim 1,

then converting the compound ~~compounds~~ of the formula (VIII) ~~are then~~ , using acids or bases or, if T represents benzyl, also hydrogenolytically, ~~converted~~ into the corresponding carboxylic acid ~~acids~~ of the formula (IX)



(IX)

in which

R^1, R^2, R^3, R^4, R^5, R^6, R^7 and R^8 are each as defined in Claim 1,

then optionally further modifying this carboxylic acid (IX) ~~these carboxylic acids (IX) are, if appropriate, modified further~~ by known esterification methods to give a compound ~~compounds~~ of the formula (I),

and optionally converting the resulting compound ~~compounds~~ of the formula (IX) or (I) ~~are, if appropriate, converted~~ into a pharmaceutically acceptable salt thereof ~~their solvates, salts and/or solvates of the salts~~ using the corresponding ~~(i) solvents and/or (ii)~~ bases or acids.

6. (cancelled)

7. (currently amended) A pharmaceutical composition ~~Medicaments,~~ comprising ~~at least one~~ a compound of claim 1 or 4 ~~the formula (I) or (I-A) as defined in Claims 1 to~~ 4 and an inert non-toxic pharmaceutically acceptable carrier ~~carriers, auxiliaries, solvents, vehicles, emulsifiers and/or dispersants~~ .

8. (cancelled)

9. (cancelled).

10. (currently amended) A method for treating or preventing ~~Use of compounds of the formula (I) or (I-A) as defined in Claims 1 to 4 for preparing medicaments for the~~

~~prophylaxis and treatment of~~ stroke, arteriosclerosis, coronary heart diseases or ~~and~~ dyslipidaemias ~~, for the prophylaxis of myocardial infarction and for the treatment of restenosis after coronary angioplasty or stenting~~ , comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4 .

11. (cancelled)

12. (new) A method for preventing myocardial infarction, comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4.

13 (new) A method for treating restenosis after coronary angioplasty or stenting, comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4.